170 related articles for article (PubMed ID: 32569424)
1. Opportunities for Quantitative Translational Modeling in Oncology.
Yates JWT; Byrne H; Chapman SC; Chen T; Cucurull-Sanchez L; Delgado-SanMartin J; Di Veroli G; Dovedi SJ; Dunlop C; Jena R; Jodrell D; Martin E; Mercier F; Ramos-Montoya A; Struemper H; Vicini P
Clin Pharmacol Ther; 2020 Sep; 108(3):447-457. PubMed ID: 32569424
[TBL] [Abstract][Full Text] [Related]
2. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
Yamazaki S
AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Pharmacology Models for Cancer Target Research.
Chen D; An X; Ouyang X; Cai J; Zhou D; Li QX
Methods Mol Biol; 2019; 1953():183-211. PubMed ID: 30912023
[TBL] [Abstract][Full Text] [Related]
4. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
[TBL] [Abstract][Full Text] [Related]
5. Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).
Foffi G; Pastore A; Piazza F; Temussi PA
Phys Biol; 2013 Aug; 10(4):040301. PubMed ID: 23912807
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of tumour response and relapse kinetics based on 34,881 patients: A question of cancer type, treatment and line of treatment.
Yates JWT; Cheung SYA
Eur J Cancer; 2021 Jun; 150():42-52. PubMed ID: 33892406
[TBL] [Abstract][Full Text] [Related]
7. From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy.
Lemaire V; Bassen D; Reed M; Song R; Khalili S; Lien YTK; Huang L; Singh AP; Stamatelos S; Bottino D; Hua F
Clin Pharmacol Ther; 2023 May; 113(5):963-972. PubMed ID: 36282521
[TBL] [Abstract][Full Text] [Related]
8. QSP-IO: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immuno-Oncology Applications.
Sové RJ; Jafarnejad M; Zhao C; Wang H; Ma H; Popel AS
CPT Pharmacometrics Syst Pharmacol; 2020 Sep; 9(9):484-497. PubMed ID: 32618119
[TBL] [Abstract][Full Text] [Related]
9. Physiological Indirect Response Model to Omics-Powered Quantitative Systems Pharmacology Model.
Uatay A; Gall L; Irons L; Tewari SG; Zhu XS; Gibbs M; Kimko H
J Pharm Sci; 2024 Jan; 113(1):11-21. PubMed ID: 37898164
[TBL] [Abstract][Full Text] [Related]
10. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
[TBL] [Abstract][Full Text] [Related]
12. Animal modeling of cancer pathology and studying tumor response to therapy.
Langdon SP
Curr Drug Targets; 2012 Nov; 13(12):1535-47. PubMed ID: 22974396
[TBL] [Abstract][Full Text] [Related]
13. Next generation oncology drug development: opportunities and challenges.
Gutierrez ME; Kummar S; Giaccone G
Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
[TBL] [Abstract][Full Text] [Related]
14. Application of pharmacometrics and quantitative systems pharmacology to cancer therapy: The example of luminal a breast cancer.
Fleisher B; Brown AN; Ait-Oudhia S
Pharmacol Res; 2017 Oct; 124():20-33. PubMed ID: 28735000
[TBL] [Abstract][Full Text] [Related]
15. The design, analysis and application of mouse clinical trials in oncology drug development.
Guo S; Jiang X; Mao B; Li QX
BMC Cancer; 2019 Jul; 19(1):718. PubMed ID: 31331301
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
17. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
Yamazaki S; Spilker ME; Vicini P
Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
[TBL] [Abstract][Full Text] [Related]
18. A mathematical model to study the effects of drugs administration on tumor growth dynamics.
Magni P; Simeoni M; Poggesi I; Rocchetti M; De Nicolao G
Math Biosci; 2006 Apr; 200(2):127-51. PubMed ID: 16516246
[TBL] [Abstract][Full Text] [Related]
19. Assessing cardiac safety in oncology drug development.
Seltzer JH; Gintant G; Amiri-Kordestani L; Singer J; Koplowitz LP; Moslehi JJ; Barac A; Yu AF
Am Heart J; 2019 Aug; 214():125-133. PubMed ID: 31202099
[No Abstract] [Full Text] [Related]
20. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
